Search

Zai Lab Ltd ADR

Suletud

SektorTervishoid

26.07 -2.76

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.03

Max

27.12

Põhinäitajad

By Trading Economics

Sissetulek

191K

-51M

Müük

6.7M

106M

Aktsiakasum

-0.46

Kasumimarginaal

-47.808

Töötajad

1,784

EBITDA

-2.1M

-46M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+51.09% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

826M

2.9B

Eelmine avamishind

28.83

Eelmine sulgemishind

26.07

Uudiste sentiment

By Acuity

50%

50%

145 / 340 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. aug 2026, 23:56 UTC

Correlated Moves
News

Royal Gold shares are higher in after-market trading following CEO Bill Heissenbuttel's upcoming presentation at the Jefferies Global Industrials Conference on September 10.

27. aug 2026, 23:56 UTC

Correlated Moves
News

Diamondback Energy has risen in after-market hours following its joint venture for the Solitude Pipeline System, with analysts estimating a fair value of $232.17.

27. aug 2026, 23:51 UTC

News

Carlyle Group reported second-quarter revenue exceeding analyst expectations. In after-market trading, shares are advancing, reflecting a solid performance backdrop.

27. aug 2026, 23:51 UTC

Correlated Moves
News

The USD/HUF is trading higher, reflecting gains since Wednesday. A decline in initial jobless claims suggests strength in the U.S. economy.

27. aug 2026, 23:31 UTC

News

NAPCO Security Technologies Inc shares are lower in after-market hours, following broader market declines despite a 10% revenue increase in the fiscal fourth quarter.

27. aug 2026, 23:26 UTC

News

Vanguard Mortgage-Backed Securities ETF is trading lower in after-market hours, amid a decline in the US 10Y Treasury Bond Index and investor sentiment shifts.

27. aug 2026, 23:11 UTC

News

Shares of Regenxbio are higher in after-market trading following a $949.4K insider purchase by director Gregor Ciongoli of 102.6K shares.

27. aug 2026, 23:06 UTC

Social Media
News

BioNTech SE's COVID-19 vaccine COMIRNATY® XFG receives FDA approval for adults 65 and older. Shares are trading higher in after-market hours.

27. aug 2026, 23:06 UTC

News

Shoals Technologies Group Inc shares declined in after-market trading despite winning a patent case against Voltage, LLC, with a jury awarding over $96 million.

27. aug 2026, 23:02 UTC

News

Permian Resources Corp shares are higher in after-market hours, boosted by Citigroup's outlook on the Permian Basin becoming the top U.S. natural gas producer.

27. aug 2026, 23:02 UTC

News

PDD Holdings reported second-quarter revenue of RMB112.4 billion, missing estimates. Shares are roughly flat in after-market trading amid rising operating expenses.

27. aug 2026, 23:02 UTC

Correlated Moves
News

Coinbase Global Inc. announced a token-backed mortgage product with Better Mortgage, boosting shares modestly higher in after-market trading.

27. aug 2026, 23:02 UTC

Social Media
News

Salesforce Inc. remains roughly flat in after-market hours amid discussions on short-selling dynamics and positive user experiences with its CRM system.

27. aug 2026, 23:02 UTC

News

Revolution Medicines Inc shares are higher in after-market trading following FDA approval of RASONQUE for metastatic pancreatic cancer, discussed during an August 26 conference call.

27. aug 2026, 23:02 UTC

News

Main Street Capital plans a supplemental dividend for December 2026, continuing its $0.30-per-share quarterly distribution. Shares are trading higher in after-market hours.

27. aug 2026, 23:02 UTC

Social Media
News

CrowdStrike Holdings Inc shares are lower in after-market hours, reflecting broader market declines despite recent strong earnings and positive revenue outlook.

27. aug 2026, 23:02 UTC

News

SFL Corporation reported Q2 revenue of $200.77 million and net income of $33.79 million. Shares are higher in after-market trading following the announcement.

27. aug 2026, 23:02 UTC

Social Media
Event
News

Gap Inc. shares rise in after-market trading following Q2 earnings that beat EPS estimates and included an adjusted EPS guidance increase.

27. aug 2026, 23:02 UTC

Social Media
News

Ulta Beauty Inc. shares are lower in after-market trading despite reporting strong second-quarter earnings and raising fiscal year guidance for net sales growth.

27. aug 2026, 23:02 UTC

News

Constellation Brands names Alex Alvarez as chief supply chain officer for its beer division. Shares are higher in after-market trading following initial dips.

27. aug 2026, 23:02 UTC

News

Rivian Automotive shares fell in after-market trading after CFO Claire McDonough announced her departure for GE Vernova, effective October 30.

27. aug 2026, 23:02 UTC

Event
Social Media
News

Affirm Holdings shares rise in after-market hours following a record fiscal fourth-quarter profit and revenue of $1.17 billion, exceeding estimates.

27. aug 2026, 23:02 UTC

Social Media
News

Pfizer and BioNTech received FDA approval for their XFG-adapted COVID-19 vaccine, COMIRNATY XFG, boosting shares in after-market trading.

27. aug 2026, 23:02 UTC

Social Media
News

Marvell Technology reported Q2 revenue of $2.74 billion, exceeding estimates, but shares are trading lower in after-market hours following the results.

27. aug 2026, 23:02 UTC

News
Correlated Moves

USD/PLN is gaining modestly today, influenced by initial jobless claims falling to 203,000, indicating ongoing strength in the labor market.

27. aug 2026, 23:02 UTC

Correlated Moves
Social Media
News

NVIDIA pauses revenue-sharing deals with AI cloud firms amid antitrust concerns, contributing to a modest decline in shares during after-market hours.

27. aug 2026, 23:02 UTC

Social Media
News

Veeva Systems Inc shares are lower in after-market trading, reflecting a broader market downturn despite earlier gains. The stock remains strong relative to its 20-day moving average.

27. aug 2026, 23:02 UTC

News

Bilibili Inc shares declined during after-market hours despite reporting strong growth in daily active users and advertising revenue. The stock remains below its 20-day moving average.

27. aug 2026, 23:01 UTC

News

Otis Worldwide Corp shares are lower in after-market trading, despite securing a significant contract for modernization at Tianjin 117 Tower in China.

27. aug 2026, 23:01 UTC

News
Correlated Moves

Intuit Inc. shares are lower in after-market trading following a downgrade by BofA Securities, which cut its fiscal 2027 revenue estimate to $23.4 billion.

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

51.09% tõus

12 kuu keskmine prognoos

Keskmine 39.33 USD  51.09%

Kõrge 45 USD

Madal 36 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

145 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat